"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Descriptor ID |
D000276
|
MeSH Number(s) |
D27.505.696.477.067
|
Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 2 | 1 | 3 |
1999 | 2 | 1 | 3 |
2000 | 2 | 0 | 2 |
2001 | 0 | 2 | 2 |
2002 | 1 | 0 | 1 |
2003 | 0 | 5 | 5 |
2004 | 9 | 1 | 10 |
2005 | 2 | 0 | 2 |
2006 | 3 | 1 | 4 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 3 | 0 | 3 |
2011 | 2 | 1 | 3 |
2012 | 1 | 0 | 1 |
2013 | 0 | 1 | 1 |
2014 | 1 | 1 | 2 |
2016 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. Front Immunol. 2022; 13:800295.
-
Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced N-glycosylation Abundance and Branching. Cancer Res. 2021 05 15; 81(10):2625-2635.
-
A cationic amphiphilic co-polymer as a carrier of nucleic acid nanoparticles (Nanps) for controlled gene silencing, immunostimulation, and biodistribution. Nanomedicine. 2020 01; 23:102094.
-
B lymphocytes confer immune tolerance via cell surface GARP-TGF-? complex. JCI Insight. 2018 04 05; 3(7).
-
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016 Apr 27; 34(19):2170-8.
-
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. Vaccine. 2016 Jan 12; 34(3):313-9.
-
Locoregional therapies in melanoma. Surg Clin North Am. 2014 Oct; 94(5):1003-15, viii.
-
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine. 2014 May 19; 32(24):2882-95.
-
Neuropsychiatric symptoms associated with topical imiquimod therapy: report of 2 cases. JAMA Dermatol. 2013 Apr; 149(4):500-1.
-
Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-?1 signaling. J Immunol. 2012 Sep 01; 189(5):2635-44.